Pediatric Vaccines Market Analysis

Pediatric Vaccines Market Analysis

To get key market trends

  Download Free Sample

Based on the type, the market is classified into monovalent vaccines and multivalent vaccines. The multivalent vaccines segment dominated the market with revenue of USD 30 billion in 2023.
 

• Multivalent vaccines protect against multiple diseases with a single injection, making them highly desirable for comprehensive disease prevention and reducing the overall number of vaccinations needed, thereby driving the growth of the medication segment in market.
   
• Also, combining multiple antigens into a single vaccine can lower production, storage, and transportation costs, making these vaccines more cost-effective for healthcare systems and organizations.
   
• Furthermore, by reducing the number of injections, multivalent vaccines improve compliance among parents and caregivers, leading to higher vaccination rates and better herd immunity, thereby driving future growth in the market.
   

Based on the technology, the global pediatric vaccines market is classified into live attenuated vaccines, inactivated vaccines, toxoid vaccines, conjugate vaccines, and other technologies. The inactivate vaccines segment dominated the market with market share of 29.3% in 2023.
 

• Inactivated vaccines which contain killed or inactivated pathogens are considered safer, especially for immunocompromised children, as they cannot cause the disease they are designed to protect against.
   
• Moreover, ongoing advancements in vaccine technology including improvements in adjuvants and delivery systems enhance the effectiveness and acceptance of inactivated vaccines, thereby fuelling the market growth.
   
• Furthermore, the global improvement in cold chain logistics and infrastructure ensures the effective storage and distribution of inactivated vaccines, especially in developing regions. Such aforementioned factor is expected to spur the segmental growth during the analysis period.
   

Based on indication, the pediatric vaccines market is classified into influenza, human papilloma virus, measles, mumps, and rubella, polio, pneumococcal disease, diphtheria, pertussis, and tetanus, and other indications. The influenza segment is expected to reach USD 33.3 billion by end of 2032.
 

• Influenza (flu) is a highly contagious respiratory illness that affects a significant number of children each year, especially during the flu season. The seasonal nature of influenza drives regular demand for influenza vaccines. Also, continuous improvements in influenza vaccine formulations such as the development of quadrivalent vaccines that offer broader protection against multiple strains, attract more consumers and healthcare providers.
   
• Furthermore, increasing awareness among parents and healthcare providers pertaining to the importance of influenza vaccination for children boosts demand, thereby contributing the market growth.
   

Based on end-use, the pediatric vaccines market is classified into public and private. The public segment is expected to exhibit 9.2% CAGR between 2024 - 2032.
 

• Government hospitals are often at the forefront of public health initiatives aimed at increasing vaccination rates among children. These initiatives include awareness campaigns, outreach programs, and school-based vaccination drives.
   
• Moreover, government hospitals often have established healthcare infrastructure and logistical capabilities that enable efficient storage, handling, and distribution of vaccines. This infrastructure supports the smooth implementation of immunization programs.
   
• Furthermore, government hospitals focus on ensuring equitable access to vaccines, particularly for underserved populations and remote areas. This commitment to health equity enhances vaccine coverage and supports market growth by reaching more children in need.
   

In 2023, North America secured a substantial market share of 48.2% in the global pediatric vaccines market and is expected to dominate throughout the forecast period.
 

• North America has a strong presence of major pharmaceutical and biotechnology companies, driving innovation and development of new vaccines and vaccine technologies. These companies invest heavily in R&D activities to bring new vaccines to the market.
   
• Moreover, strong public awareness campaigns and educational initiatives about the benefits of vaccination encourage high vaccination uptake rates among parents and caregivers supports market growth.  
   
• In addition, collaborations between academia, pharmaceutical companies, and government agencies drive innovation in pediatric vaccines, leading to the development of new vaccines and improvements in existing ones, thereby contributing the growth of the market in the U.S.
   

Germany to experience the highest growth rate in the Europe pediatric vaccines market.
 

• Germany has a well-established healthcare system with strong government policies supporting vaccination programs. Comprehensive coverage under statutory health insurance encourages high vaccination rates among children, thereby fostering the market growth.
   
• Moreover, extensive public health campaigns and education programs emphasize the importance of childhood immunization, increasing parental acceptance and demand for vaccines play a significant role in country level market growth.
   

The Asia Pacific pediatric vaccines market is expected to grow with a significant CAGR of 9.3% during the forecast period.
 

• Rapid population growth in Asia-Pacific region particularly in urban areas increases the demand for vaccines to protect against infectious diseases, as the region comprises higher population density and increased disease transmission risk. Also, strong government commitment to immunization programs and initiatives aimed at expanding vaccine coverage and access, often supported by international organizations such as WHO and UNICEF will help to achieve complete vaccination to population. Such aforementioned factor is expected to augment the regional market growth.